panel discussion

What is the strategy for "bridging" world-class research results to society!

A panel discussion entitled "The Japan Society for Hyperdifferentiated Fields, Osaka 2022 (Saturday, August 27, 2022)" will be held within theWhat is the strategy for "bridging" world-class research results to society!(Session Partner: Japan Autophagy Consortium).

Hyper Interdisciplinary Conference in Osaka 2022

The more impactful a research result is, the more likely it is that only its keywords and convenient aspects will be taken up and carried by itself. While it is good to be known to the general public, a wrong understanding can lead to the destruction of new markets that were supposed to be opened up by the newly gained scientific knowledge. Furthermore, it may even damage the original social value of the research results. What can we do to ensure that the benefits of valuable research results are properly disseminated to society and returned to industry? I would like to discuss the social return of research results in Nobel Prize-winning Japan, including two examples and the formation of a culture for social acceptance. In this issue, we will focus on two research topics, autophagy and immune checkpoint inhibition, in the context of the health industry and pharmaceutical applications.

We will have a program of discussions among researchers, startups, and large companies from a variety of perspectives, not limited to the themes of this session. For more information,Conference Websitefor more information.

*The event will be held after taking measures against new coronavirus infection on the day of the event.

What is the strategy for "bridging" world-class research results to society!

Date: Saturday, August 27, 2022, 16:20-17:10
Location: Knowledge Capital Conference Room Tower C
Details:https://hic.lne.st/conference/osaka2022/

speaker

Ms. Miwako Ishido
President and Representative Director, AutoPhagyGO, Inc.

Graduated from the University of Tokyo, Faculty of Science, and Kyoto University. Doctor of Science. After working as a post-doctoral fellow at The Scripps Research Institute and as a senior researcher at R & R Corporation, he worked in marketing and medical affairs at foreign pharmaceutical companies Janssen Pharma K.K. and AbbVie LLC From 2019, he will also serve as a director of AutoPhagyGO Inc. Since June 2020, he has been dedicated to the position of President and Representative Director of AutoPhagyGO, Inc.

Mr. Kenji Chamoto
Department of Immunogenomic Medicine, Cancer Center for Immunology and Immunology (CCII), Graduate School of Medicine, Kyoto University, Japan.

D. in Medicine from Hokkaido University. D. in Medicine from Hokkaido University, Assistant Professor at the Institute for Gene Disease Control, Postdoctoral fellow at Harvard Medical School and the Ontario Cancer Institute, Assistant Professor and Lecturer at the Graduate School of Medicine, Kyoto University, and Associate Professor at the Graduate School of Medicine, Kyoto University. He received the 100th American Cancer Society Highly Rated Paper Award, the 13th Japanese Association for Cancer Immunology Young Investigator Award, the 36th Molecular Biology Society of Japan Travel Award, the American Immunological Association AAI Trainee Abstract Award, the 43rd Japanese Association for Immunology UHN ORT Conference Travel Award, the 76th Japanese Cancer Association Encouragement Award, the 9th Kiyoko Goto and Paul Burdari Science Award, and the Special Award. His research interests include tumor immunity, immunometabolism, and autoimmunity.

Mr. Masaru Kado
Representative Director and CEO, Filament Co.

Born in 1972, Mr. Kuroda has been working as a new business creation specialist since 2015, mainly at large companies, providing comprehensive support from finding the right people for business development and generating business ideas to commercializing them. He has established a unique method to improve the success rate of business by injecting necessary information and introducing key personnel at the right time, increasing the value of the business idea and the motivation of the person in charge, using the wide range of knowledge and personal connections across various industries that he has cultivated since his previous job (as a public servant). He has established a unique method to increase the value of business proposals and the motivation of the people in charge, thereby improving the success rate of business projects.

[Moderator].
Inoue, Jyo
CKO, President and Representative Director, Liverness, Inc.

D., Pharmacist, Graduate School of Pharmaceutical Sciences, Tokyo University of Pharmacy and Life Sciences, founded REVANES in 2002 with only undergraduate and graduate students of science and technology while in graduate school. After completing the doctoral process, he worked as Assistant Professor and Lecturer at the Faculty of Science, Kitasato University, Assistant Professor at the Graduate School of Medicine, Kyoto University, and Specially Appointed Associate Professor at Keio University, before assuming and concurrently serving as Professor of Advanced Pharmaceutical Sciences at the Faculty of Pharmaceutical Sciences, Kumamoto University and Visiting Professor at the Faculty of Pharmaceutical Sciences, Keio University from 2018. While conducting research and development, he has been involved in launching joint research projects with universities and research institutions and supporting the establishment of research institutes. He has also been involved in the launch of many venture companies and serves as an advisor.

Hyper Interdisciplinary Conference in Osaka 2022